Applied Genetic Technologies Corp., of Gainesville, Fla., said it stands to received a $10 million milestone payment from Biogen Inc., of Cambridge, Mass., triggered by the enrollment of the first patient in the second cohort of the phase I/II study testing its AAV-based gene therapy in X-linked retinitis pigmentosa.